Mazdutide
The world's first approved dual GLP-1/glucagon receptor agonist, developed by Innovent Biologics (China). Approved in China for obesity and type 2 diabetes. Phase 3 trials showed up to 20.1% weight loss.
What is Mazdutide?
Mazdutide (IBI362/LY3305677, brand name Xinermei) is a synthetic oxyntomodulin analog with a C18 fatty acid side chain enabling once-weekly subcutaneous dosing. It is a dual agonist of both GLP-1 and glucagon receptors — the same mechanism as survodutide but developed independently by Innovent Biologics in China, with Eli Lilly holding rights outside China. In June 2025, it became the world's first approved dual GCG/GLP-1 receptor agonist when China's NMPA approved it for weight management, followed by type 2 diabetes approval in September 2025. Phase 3 trials showed up to 20.1% weight loss at 9 mg (GLORY-2) and in a head-to-head trial against semaglutide, 48% vs 21% of patients achieved the combined endpoint of HbA1c <7% plus 10%+ weight loss. It is not FDA or EMA approved and no US filing has been announced.
Why People Talk About It
Weight loss rivaling tirzepatide (up to 20.1%)
ModerateSuperior glycemic control vs semaglutide in head-to-head trial
ModerateFirst-in-class dual GCG/GLP-1 agonist approval
ModerateGlucagon-mediated energy expenditure increase
EmergingHow It Works
Mazdutide activates two receptors: GLP-1 (which reduces appetite and improves blood sugar) and glucagon (which increases energy expenditure and promotes fat burning in the liver). The combination means you eat less AND burn more — a dual approach that neither receptor alone achieves as effectively.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Approved only in China — not FDA or EMA approved
- • GI side effects are dose-dependent; slower titration improves tolerability
- • Glucagon receptor activation may raise hepatic glucose output transiently
- • Long-term safety data beyond clinical trial durations is limited
What We Don't Know
Cardiovascular outcomes data is not yet available. Whether the glucagon component confers additional liver or metabolic benefits beyond GLP-1 alone in long-term use is still being studied. Western market safety data and regulatory review have not occurred.
Published Research
9 studiesEfficacy and safety of mazdutide in Chinese adults with obesity: GLORY-2 trial.
Efficacy and safety of mazdutide versus semaglutide in Chinese adults with type 2 diabetes (DREAMS-3).
Mazdutide versus dulaglutide for type 2 diabetes in China: a randomized, double-blind, active-controlled Phase 3 trial (DREAMS-2).
Mazdutide for type 2 diabetes: a randomized, double-blind, placebo-controlled Phase 3 trial (DREAMS-1).
Mazdutide, a dual glucagon-like peptide 1 and glucagon receptor agonist for the treatment of obesity in Chinese adults: a multicentre, randomised, double-blind, parallel-controlled, dose-finding, phase 3 trial (GLORY-1).
GLP-1/glucagon receptor dual agonists for obesity and type 2 diabetes: a systematic review and meta-analysis.
Mazdutide: First Approval.
Efficacy of mazdutide (IBI362) on body composition in Chinese adults with overweight or obesity.
Safety, tolerability, and pharmacokinetics of mazdutide (IBI362), a dual GLP-1/glucagon receptor agonist: Phase 1b study.
Related Peptides
Survodutide
EmergingAn investigational dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Not FDA-approved. Phase 2 trials showed up to 14.9% weight loss at 46 weeks and significant MASH resolution — Phase 3 SYNCHRONIZE program is underway.
Semaglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Tirzepatide
StrongBeginnerA dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Retatrutide
EmergingAn investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.
Liraglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.
Dulaglutide
StrongBeginnerA once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes, with proven cardiovascular benefits and moderate weight loss effects.
Quick Facts
- Class
- Incretin Mimetic
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 9PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.